CD105与脉络膜新生血管  

CD105 and choroidal neovascularization

作　　者：徐建锋[1] 王雨生[1] 

机构地区：[1]第四军医大学西京医院眼科全军眼科研究所,中国陕西省西安市710032

出　　处：《国际眼科杂志》2008年第1期126-128,共3页International Eye Science

基　　金：中国陕西省自然科学基金资助(No.2004C246);第四军医大学西京医院科技创新基金资助(No.XJCX04M003)~~

摘　　要：CD105(endoglin)为一种同型二聚体的膜结合性糖蛋白,是转化生长因子-β(transforming growth factor,TGF-β)受体超家族的成员之一。它参与TGF-β受体的信号转导,调节细胞对TGF-β的反应,在新生血管组织及肿瘤组织边缘部分血管起源的内皮细胞中高度表达,是新生血管的标志物之一。脉络膜新生血管(choroidal neovasculariza-tion,CNV)的生成是年龄相关性黄斑变性(age-related macular degeneration,AMD)、眼拟组织胞浆菌病综合征(presumed ocular histoplasmosis syndrome,POHS)和病理性近视黄斑变性等CNV相关疾病的的主要病理特征。近年研究表明,CD105与CNV密切相关,可能成为治疗CNV重要的靶分子之一。CD105 （endoglin）, as one of the transforming growth factor-β（TGF-β） superfamily, is a homodimeric transmem-brane glycoprotein involved in TGF-β receptor＇s signal transduction and modulating cellular responses to TGF-β. CD105 is a marker of new vessel, which is highly expressed in the neovascular tissues and in angiogenic endothelial cells on the marginal part of malignant tumors. Choroidal neovascularization （CNV） is the main pathologic characteristic of ocular CNV diseases such as age-related macular degeneration （AMD）, presumed ocular histoplasmosis syndrome （POHS） and pathologic myopia and so on. Studies indicate that CD105 is closely ,correlated with CNV and may be an important molecular target to treat CNV in recent years.

关 键 词：CD105 脉络膜新生血管 转化生长因子-Β 

分 类 号：R773.4[医药卫生—眼科]